 |
|
Response of Thyrotropin to Thyrotropin-Releasing Hormone as Predictor of Treatment OutcomePrediction of Recovery and Relapse in Treatment With Antidepressants and Neuroleptics
Gerhard Langer, MD;
Greta Koinig, MD;
Reinhold Hatzinger, PhD;
Georg Schönbeck, MD;
Franz Resch, MD;
Harald Aschauer, MD;
Matcheri S. Keshavan, MD;
Werner Sieghart, PhD
Arch Gen Psychiatry. 1986;43(9):861-868.
Abstract
• We determined whether the response of thyrotropin (TSH) to thyrotropin-releasing hormone could predict the outcome of treatment with antidepressant and neuroleptic drugs. We studied 114 female patients diagnosed as having major and minor depressive, manic, schizoaffective, and schizophrenic disorders. A blunted TSH response (<5 µU/mL [<5 mU/L]) at admission was associated with recovery after nine weeks of inpatient treatment using clomipramine hydrochloride for depression and haloperidol for psychosis. A blunted TSH response at discharge was associated with early relapse in depressives receiving clomipramine maintenance therapy. Our findings support the notion that the thyrotropin-releasing hormone test is a "state" marker that may be of use in predicting the outcome of treatment with antidepressant and neuroleptic drugs.
Author Affiliations
From the Psychobiological Research Unit, Department of Psychiatry, University of Vienna.
Footnotes
Accepted for publication Nov 25, 1985.
Reprint requests to Psychobiological Research Unit, Department of Psychiatry, University of Vienna, Lazarettgasse 14, A-1090 Vienna, Austria (Dr Langer).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Thyrotropin, but not a polymorphism in type II deiodinase, predicts response to paroxetine in major depression.
Brouwer et al.
Eur J Endocrinol 2006;154:819-825.
ABSTRACT
| FULL TEXT
A Structured Interview Guide for the Hamilton Depression Rating Scale
Williams
Arch Gen Psychiatry 1988;45:742-747.
ABSTRACT
|
